Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization

被引:73
作者
Messer, William B. [1 ]
Yount, Boyd [2 ]
Hacker, Kari E. [3 ,4 ]
Donaldson, Eric F. [2 ]
Huynh, Jeremy P. [2 ]
de Silva, Aravinda M. [3 ,4 ]
Baric, Ralph S. [2 ]
机构
[1] Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC 27514 USA
[2] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[3] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Sch Med, SE Reg Ctr Excellence Biodef & Emerging Infect Di, Chapel Hill, NC USA
基金
美国国家卫生研究院;
关键词
TYPE-4 VACCINE CANDIDATE; LENGTH INFECTIOUS CDNA; UNTRANSLATED REGION; ANTIBODY-RESPONSE; CORONAVIRUS; RECOMBINANT; AMERICAN; REPLICATION; DISEASE; RNA;
D O I
10.1371/journal.pntd.0001486
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Dengue viruses (DENV) are enveloped single-stranded positive-sense RNA viruses transmitted by Aedes spp. mosquitoes. There are four genetically distinct serotypes designated DENV-1 through DENV-4, each further subdivided into distinct genotypes. The dengue scientific community has long contended that infection with one serotype confers lifelong protection against subsequent infection with the same serotype, irrespective of virus genotype. However this hypothesis is under increased scrutiny and the role of DENV genotypic variation in protection from repeated infection is less certain. As dengue vaccine trials move increasingly into field-testing, there is an urgent need to develop tools to better define the role of genotypic variation in DENV infection and immunity. To better understand genotypic variation in DENV-3 neutralization and protection, we designed and constructed a panel of isogenic, recombinant DENV-3 infectious clones, each expressing an envelope glycoprotein from a different DENV-3 genotype; Philippines 1982 (genotype I), Thailand 1995 (genotype II), Sri Lanka 1989 and Cuba 2002 (genotype III) and Puerto Rico 1977 (genotype IV). We used the panel to explore how natural envelope variation influences DENV-polyclonal serum interactions. When the recombinant viruses were tested in neutralization assays using immune sera from primary DENV infections, neutralization titers varied by as much as similar to 19-fold, depending on the expressed envelope glycoprotein. The observed variability in neutralization titers suggests that relatively few residue changes in the E glycoprotein may have significant effects on DENV specific humoral immunity and influence antibody mediated protection or disease enhancement in the setting of both natural infection and vaccination. These genotypic differences are also likely to be important in temporal and spatial microevolution of DENV-3 in the background of heterotypic neutralization. The recombinant and synthetic tools described here are valuable for testing hypotheses on genetic determinants of DENV-3 immunopathogenesis.
引用
收藏
页数:12
相关论文
共 67 条
[1]   Neutralizing antibody response variation against dengue 3 strains [J].
Alvarez, Mayling ;
Pavon-Oro, Alequis ;
Rodriguez-Roche, Rosmari ;
Bernardo, Lidice ;
Morier, Luis ;
Sanchez, Lizet ;
Alvarez, Angel M. ;
Guzman, Maria G. .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (10) :1783-1789
[2]   Genetic diversity of the E Protein of Dengue Type 3 Virus [J].
Amarilla, Alberto A. ;
de Almeida, Flavia T. ;
Jorge, Daniel M. ;
Alfonso, Helda L. ;
de Castro-Jorge, Luiza A. ;
Nogueira, Nadia A. ;
Figueiredo, Luiz T. ;
Aquino, Victor H. .
VIROLOGY JOURNAL, 2009, 6
[3]  
[Anonymous], 1997, DENGUE DENGUE HEMORR
[4]   Phylogeography and evolutionary history of dengue virus type 3 [J].
Araujo, Joselio M. G. ;
Nogueira, Rita M. R. ;
Schatzmayr, Hermann G. ;
Zanotto, Paolo M. de A. ;
Bello, Gonzalo .
INFECTION GENETICS AND EVOLUTION, 2009, 9 (04) :716-725
[5]   Differential Susceptibility of Aedes aegypti to Infection by the American and Southeast Asian Genotypes of Dengue Type 2 Virus [J].
Armstrong, Philip ;
Rico-Hesse, Rebeca .
VECTOR-BORNE AND ZOONOTIC DISEASES, 2001, 1 (02) :159-+
[6]   Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegpti [J].
Armstrong, PM ;
Rico-Hesse, R .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 68 (05) :539-544
[7]   Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice [J].
Becker, Michelle M. ;
Graham, Rachel L. ;
Donaldson, Eric F. ;
Rockx, Barry ;
Sims, Amy C. ;
Sheahan, Timothy ;
Pickles, Raymond J. ;
Corti, Davide ;
Johnston, Robert E. ;
Baric, Ralph S. ;
Denison, Mark R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (50) :19944-19949
[8]   Genetically modified, live attenuated dengue virus type 3 vaccine candidates [J].
Blaney, JE ;
Hanson, CT ;
Firestone, CY ;
Hanley, KA ;
Murphy, BR ;
Whitehead, SS .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2004, 71 (06) :811-821
[9]   Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 [J].
Blaney, JE ;
Hanson, CT ;
Hanley, KA ;
Murphy, BR ;
Whitehead, SS .
BMC INFECTIOUS DISEASES, 2004, 4 (1)
[10]   Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys [J].
Blaney, JE ;
Matro, JM ;
Murphy, BR ;
Whitehead, SS .
JOURNAL OF VIROLOGY, 2005, 79 (09) :5516-5528